Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Genotype and phenotype spectrum of NRAS germline variants

Altmüller, F., Lissewski, C., Bertola, D., Flex, E., Stark, Z., Spranger, S., Baynam, G., Buscarilli, M., Dyack, S., Gillis, J., Yntema, H.G., Pantaleoni, F., van Loon, R.L.E., MacKay, S., Mina, K., Schanze, I., Tan, T.Y., Walsh, M., White, S.M., Niewisch, M.R., García-Miñaúr, S., Plaza, D., Ahmadian, M.R., Cavé, H., Tartaglia, M. and Zenker, M. (2017) Genotype and phenotype spectrum of NRAS germline variants. European Journal of Human Genetics, 25 (7). pp. 823-831.

Link to Published Version:
*Subscription may be required


RASopathies comprise a group of disorders clinically characterized by short stature, heart defects, facial dysmorphism, and varying degrees of intellectual disability and cancer predisposition. They are caused by germline variants in genes encoding key components or modulators of the highly conserved RAS-MAPK signalling pathway that lead to dysregulation of cell signal transmission. Germline changes in the genes encoding members of the RAS subfamily of GTPases are rare and associated with variable phenotypes of the RASopathy spectrum, ranging from Costello syndrome (HRAS variants) to Noonan and Cardiofaciocutaneous syndromes (KRAS variants). A small number of RASopathy cases with disease-causing germline NRAS alterations have been reported. Affected individuals exhibited features fitting Noonan syndrome, and the observed germline variants differed from the typical oncogenic NRAS changes occurring as somatic events in tumours. Here we describe 19 new cases with RASopathy due to disease-causing variants in NRAS. Importantly, four of them harbored missense changes affecting Gly12, which was previously described to occur exclusively in cancer. The phenotype in our cohort was variable but well within the RASopathy spectrum. Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour. With this report, we expand the genotype and phenotype spectrum of RASopathy-associated germline NRAS variants and provide evidence that NRAS variants do not spare the cancer-associated mutation hotspots.

Item Type: Journal Article
Murdoch Affiliation(s): Institute for Immunology and Infectious Diseases
Publisher: Nature Publishing Group
Copyright: © Springer Nature.
Item Control Page Item Control Page